Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness
暂无分享,去创建一个
Rachel B. Keller | D. Lin | G. Oxnard | A. Schrock | R. Huang | A. Mahipal | R. Graf | Gerald Li | J. Quintanilha | S. Chakrabarti | J. Ross | Richard S. P. Huang | M. Storandt
[1] D. Lin,et al. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden , 2023, JAMA network open.
[2] A. Jemal,et al. Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.
[3] M. Levy,et al. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer , 2022, JAMA network open.
[4] You Shuai,et al. Tumor mutation burden determined by a 645-cancer gene panel and compared with microsatellite instability and mismatch repair genes in colorectal cancer. , 2021, Journal of gastrointestinal oncology.
[5] N. Schultz,et al. Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. , 2021, JAMA oncology.
[6] J. Roth,et al. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer , 2021, Journal for ImmunoTherapy of Cancer.
[7] Seung‐Mo Hong,et al. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions , 2021, Cancers.
[8] Anala Gossai,et al. Validation analysis of a composite real‐world mortality endpoint for patients with cancer in the United States , 2021, Health services research.
[9] J. Chabot,et al. Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far. , 2021, Seminars in oncology.
[10] Robert Tibshirani,et al. Penalized regression for left‐truncated and right‐censored survival data , 2021, Statistics in medicine.
[11] Yongsheng Wang,et al. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma. , 2020, Lung cancer.
[12] M. Karamouzis,et al. Immunotherapy for pancreatic cancer: A 2020 update. , 2020, Cancer treatment reviews.
[13] M. Chiu,et al. A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer , 2020, Translational lung cancer research.
[14] Myung Ah Lee,et al. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.
[15] V. Balachandran,et al. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. , 2019, Gastroenterology.
[16] David Bourque,et al. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database , 2019, JAMA.
[17] Saman Maleki Vareki,et al. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors , 2018, Journal of Immunotherapy for Cancer.
[18] D. Felsher,et al. The MYC oncogene is a global regulator of the immune response. , 2018, Blood.
[19] Philip J. Stephens,et al. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal , 2018, PLoS Comput. Biol..
[20] Levi Garraway,et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.
[21] Alberto Mantovani,et al. Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.
[22] D. Weaver,et al. Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy , 2016, Nature Medicine.
[23] Zoltan Szallasi,et al. Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations , 2013, PloS one.
[24] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[25] David Atkins,et al. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[26] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.